Key Takeaway: GlyphCBD (SPT-310) has demonstrated significant inhibition of seizure activity in the Maximal Electroshock Seizure Model. This lymphatic-targeting prodrug of cannabidiol shows promise in treating seizure disorders. The results suggest a potential new therapeutic avenue for patients suffering from epilepsy.
Market Sentiment Analysis
POSITIVE FACTORS
GlyphCBD shows significant efficacy in reducing seizure activity.
The prodrug targets lymphatic systems, potentially enhancing treatment.
Research indicates promising results in a preclinical model.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - December 8, 2025
GlyphCBD (SPT-310), a Lymphatic-Targeting Prodrug of Cannabidiol, Significantly Inhibits Seizure Activity in the Maximal Electroshock Seizure Model
Frequently Asked Questions
What is GlyphCBD (SPT-310)?
GlyphCBD (SPT-310) is a lymphatic-targeting prodrug of cannabidiol.
How does GlyphCBD affect seizures?
GlyphCBD significantly inhibits seizure activity in the Maximal Electroshock Seizure Model.
What model was used in the study?
The study utilized the Maximal Electroshock Seizure Model to evaluate efficacy.
What is the potential benefit of GlyphCBD?
GlyphCBD may provide a new therapeutic option for patients with epilepsy.